Arancha Cebrián
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arancha Cebrián has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Juan Carlos Lacal
Department of Metabolic & Immune Diseases, Instituto de Investigaciones Biomédicas, Agencia Estatal Consejo Superior de Investigaciones Científicas, Madrid, Spain
2 shared publications - Carlos Alberto Gonzalez
Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain
1 shared publication - Carlos Camps
Hospital General Universitario de Valencia, Valencia, Spain
1 shared publication E. Ardanaz
Navarre Public Health Institute, Pamplona, Spain
1 shared publicationElsa Sánchez-López
1 shared publication- Juan Casado-Vela
Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Pozuelo, 28223 Madrid, Spain
1 shared publication
Latest Publications
- 30 July 2013
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 16 (1) , 107-112
Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility
Aim The relevance of the cytidine diphosphate-choline and Rho GTPases pathways in the pathogenesis of cancer has been previously demonstrated. We investigate by a case–control association study if genetics variants in these pathways are associated with risk of developing lung cancer. Methods Thirty-seven tag SNPs were evaluated as risk factor of NSCLC in 897 cases and 904 controls. Results Six SNPs were nominally associated with lung cancer risk, which were not significant after the Bonferroni correction for multiple comparisons. No association was observed with the remaining 31 analyzed SNPs, neither it was found significant in haplotype frequencies. Conclusions Although the implication of the two pathways investigated in our study in carcinogenesis is well established, our null results suggest that common genetic variants in CDP-choline and Rho GTPases-related genes are not risk factors for lung cancer.
- 30 July 2013
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 16 (1) , 107-112
Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility
Aim The relevance of the cytidine diphosphate-choline and Rho GTPases pathways in the pathogenesis of cancer has been previously demonstrated. We investigate by a case–control association study if genetics variants in these pathways are associated with risk of developing lung cancer. Methods Thirty-seven tag SNPs were evaluated as risk factor of NSCLC in 897 cases and 904 controls. Results Six SNPs were nominally associated with lung cancer risk, which were not significant after the Bonferroni correction for multiple comparisons. No association was observed with the remaining 31 analyzed SNPs, neither it was found significant in haplotype frequencies. Conclusions Although the implication of the two pathways investigated in our study in carcinogenesis is well established, our null results suggest that common genetic variants in CDP-choline and Rho GTPases-related genes are not risk factors for lung cancer.
- 21 January 2013
- Published by Cambridge University Press (CUP)
- p. 54-76
Biological Methods for Metabolic Research
- 21 January 2013
- Published by Cambridge University Press (CUP)
- p. 54-76
Biological Methods for Metabolic Research